NCT00187174View on ClinicalTrials.gov

Everolimus for Treating Pediatric Patients With Recurrent or Refractory Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

October 31, 2004

Primary Completion Date

October 31, 2008

Study Completion Date

October 31, 2008

Conditions
TumorsBrain TumorsRhabdomyosarcomaSarcoma, Soft Tissue
Interventions
DRUG

Everolimus

The drug is given orally in 28 day courses.

Trial Locations (1)

38105

St. Jude Children's Research Hospital, Memphis

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

St. Jude Children's Research Hospital

OTHER